These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 29903928)
1. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. Krebs S; Ahad A; Carter LM; Eyquem J; Brand C; Bell M; Ponomarev V; Reiner T; Meares CF; Gottschalk S; Sadelain M; Larson SM; Weber WA J Nucl Med; 2018 Dec; 59(12):1894-1900. PubMed ID: 29903928 [TBL] [Abstract][Full Text] [Related]
2. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. Wei LH; Olafsen T; Radu C; Hildebrandt IJ; McCoy MR; Phelps ME; Meares C; Wu AM; Czernin J; Weber WA J Nucl Med; 2008 Nov; 49(11):1828-35. PubMed ID: 18927335 [TBL] [Abstract][Full Text] [Related]
3. Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene. Sellmyer MA; Richman SA; Lohith K; Hou C; Weng CC; Mach RH; O'Connor RS; Milone MC; Farwell MD Mol Ther; 2020 Jan; 28(1):42-51. PubMed ID: 31668558 [TBL] [Abstract][Full Text] [Related]
4. Feasibility study of Wang XY; Wang Y; Wu Q; Liu JJ; Liu Y; Pan DH; Qi W; Wang LZ; Yan JJ; Xu YP; Wang GJ; Miao LY; Yu L; Yang M Acta Pharmacol Sin; 2021 May; 42(5):824-831. PubMed ID: 32901086 [TBL] [Abstract][Full Text] [Related]
5. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors. Murty S; Labanieh L; Murty T; Gowrishankar G; Haywood T; Alam IS; Beinat C; Robinson E; Aalipour A; Klysz DD; Cochran JR; Majzner RG; Mackall CL; Gambhir SS Cancer Res; 2020 Nov; 80(21):4731-4740. PubMed ID: 32958548 [TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study. Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW Front Immunol; 2021; 12():715000. PubMed ID: 34819930 [TBL] [Abstract][Full Text] [Related]
7. Spatio-temporal biodistribution of Sta Maria NS; Khawli LA; Pachipulusu V; Lin SW; Zheng L; Cohrs D; Liu X; Hu P; Epstein AL; Jacobs RE Sci Rep; 2021 Jul; 11(1):15077. PubMed ID: 34302002 [TBL] [Abstract][Full Text] [Related]
8. Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with Leland P; Kumar D; Nimmagadda S; Bauer SR; Puri RK; Joshi BH J Transl Med; 2023 Jun; 21(1):367. PubMed ID: 37286997 [TBL] [Abstract][Full Text] [Related]
9. Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation. Feng L; Hu W; Zeng X; Wei Z; Long Y; Li M; Sun S; Guo Z; Lan X; Zhang X; Zhuang R; Jiang D Mol Pharm; 2024 Sep; 21(9):4386-4394. PubMed ID: 39046432 [TBL] [Abstract][Full Text] [Related]
10. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370 [TBL] [Abstract][Full Text] [Related]
11. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720 [TBL] [Abstract][Full Text] [Related]
12. Enhancing Treatment Efficacy of Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544 [TBL] [Abstract][Full Text] [Related]
13. A single-chain antibody generation system yielding CAR-T cells with superior antitumor function. Ochi T; Maruta M; Tanimoto K; Kondo F; Yamamoto T; Kurata M; Fujiwara H; Masumoto J; Takenaka K; Yasukawa M Commun Biol; 2021 Mar; 4(1):273. PubMed ID: 33654176 [TBL] [Abstract][Full Text] [Related]
15. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells]. Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075 [No Abstract] [Full Text] [Related]
16. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536 [TBL] [Abstract][Full Text] [Related]
17. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. Dobrenkov K; Olszewska M; Likar Y; Shenker L; Gunset G; Cai S; Pillarsetty N; Hricak H; Sadelain M; Ponomarev V J Nucl Med; 2008 Jul; 49(7):1162-70. PubMed ID: 18552144 [TBL] [Abstract][Full Text] [Related]
18. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107 [TBL] [Abstract][Full Text] [Related]
19. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Benešová M; Umbricht CA; Schibli R; Müller C Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475 [TBL] [Abstract][Full Text] [Related]